Skip to main content

Marcella Sarzotti-Kelsoe

Research Professor of Integrative Immunobiology
Integrative Immunobiology
DUMC Box 102800, Durham, NC 27710
2 Genome Ct., Msrbii Rm 1089, Durham, NC 27710

Selected Grants


External Quality Assurance Program Oversight Laboratory (EQAPOL)

ResearchInvestigator · Awarded by National Institutes of Health · 2024 - 2031

Neutralizing Antibody Assessment to Support bnAb Production

ResearchDirector · Awarded by Advanced Bioscience Laboratories, Inc. · 2024 - 2028

HIV Vaccine Trials Network Laboratory Center

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Center · 2022 - 2027

ABL PGDM14 BIJ93.LS Stability Testing Program (Opt 1)

ResearchDirector · Awarded by Advanced Bioscience Laboratories, Inc. · 2024 - 2027

CISA 2023-03 Task 4 Lead - COVID immunogenicity

ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2023 - 2026

Protein Production Facility

ResearchInvestigator · Awarded by Bill and Melinda Gates Foundation · 2022 - 2026

NIAID Virology Quality Assurance - Year 6 Option 5

ResearchQuality Management Coordinator · Awarded by National Institutes of Health · 2019 - 2026

Immunogenicity (Serum IgG)

ResearchInvestigator · Awarded by Uvax Bio, LLC · 2024 - 2026

Neutralizing Antibody Assessment for UVAX-HIV-101 Human Clinical Trial Study

ResearchDirector · Awarded by Uvax Bio, LLC · 2024 - 2026

HVTN Laboratory Center: Phase 1 PF

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Center · 2022 - 2025

Antibody Dynamics for BNT165b1

ResearchResearch Associate · Awarded by BioNTech SE · 2023 - 2025

CIVICS Component A - Option 5

ResearchQA Liaison · Awarded by National Institutes of Health · 2019 - 2025

CIVICS A - Option 21A Equitable Adjustment

ResearchDirector · Awarded by National Institutes of Health · 2022 - 2025

CIVICS A - Option 21A

ResearchDirector · Awarded by National Institute of Allergy and Infectious Diseases · 2021 - 2025

Neutralizing Antibody Assessment for SARS-CoV-2 Vaccine Trials

ResearchDirector · Awarded by Vaccine Company, Inc. · 2023 - 2025

Nonhuman Primate Option 6

ResearchCo Investigator · Awarded by National Institutes of Health · 2018 - 2025

Moderma COVID/Flu 1083-P301

ResearchDirector · Awarded by Moderna Therapeutics, Inc. · 2024 - 2025

Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses - Option 5

ResearchQA Liaison · Awarded by National Institutes of Health · 2023 - 2024

HVTN 706

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Center · 2023 - 2024

CoVPN 5001 A Prospective Study of Acute Immune Responses to SARS-CoV-2 Infection

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Center · 2022 - 2024

CISA Maternal COVID Immunogenicity

ResearchDirector, QA/QC · Awarded by Centers for Disease Control and Prevention · 2022 - 2024

CISA COVID Flu Immunogenicity

ResearchDirector, QA/QC · Awarded by Centers for Disease Control and Prevention · 2022 - 2024

CISA COVID Peds Immunogenicity

ResearchDirector, QA/QC · Awarded by Centers for Disease Control and Prevention · 2022 - 2024

EQAPOL - Years 2017 to 2024 - BASE

ResearchDirector, QA/QC · Awarded by National Institutes of Health · 2017 - 2024

EQAPOL OPTION 6 (YEAR 7)

ResearchQuality Management Coordinator · Awarded by National Institutes of Health · 2017 - 2024

Moderna mRNA1275 P205 Trial Neutralizing Antibody Assessment

ResearchDirector · Awarded by Moderna Therapeutics, Inc. · 2021 - 2024

HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Center · 2022 - 2023

HVTN Laboratory Center: 702 PF

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Center · 2020 - 2023

Moderna mRNA-1273 P201 (Part B) Trial Neutralizing Antibody Assessment

ResearchDirector · Awarded by Moderna Therapeutics, Inc. · 2021 - 2023

HVTN 705 Case Control Janssen

ResearchInvestigator · Awarded by Fred Hutchinson Cancer Center · 2021 - 2022

Protein Production Facility

ResearchDirector, QA/QC · Awarded by Bill and Melinda Gates Foundation · 2016 - 2022

Neutralizing antibody assessment for EID 030 SARS-CoV-2 Vaccine Phase I trial

ResearchDirector · Awarded by Henry M. Jackson Foundation · 2021 - 2022

HVTN Laboratory Center: Phase 1 PF

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2020 - 2022

CoVPN 5001 A prospective study of acute immune responses to SARS-CoV2 infection - LAB

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2020 - 2022

HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2020 - 2022

HVTN 705 Pilot

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2020 - 2021

HVTN Laboratory Center: P5 PF

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2020 - 2021

Immunologic control of HIV-1 through combination bNAbs and biologics

ResearchDirector, QA/QC · Awarded by Rockefeller University · 2020 - 2021

Sc2i

ResearchAuditor · Awarded by Henry M. Jackson Foundation · 2020 - 2021

HVTN Laboratory Center: HVTN Phase 1

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2015 - 2020

HVTN Laboratory Center: HVTN 118

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2006 - 2020

SC2i

ResearchQA Liaison · Awarded by Henry M. Jackson Foundation · 2014 - 2020

HVTN TB Correlates Pilot Studies Supplement

ResearchQA Liaison · Awarded by Fred Hutchinson Cancer Research Center · 2019 - 2019

HVTN Laboratory Center: HVTN 118

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2017 - 2018

HVTN Laboratory Center: HVTN 117

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2017 - 2018

HVTN - A004

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2015 - 2018

HIV Vaccine Trials Network: LC P5 PF

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2015 - 2018

Nonhuman Primate Core-Option 6

ResearchCo Investigator · Awarded by National Institutes of Health · 2012 - 2018

EQAPOL Option 47

ResearchInvestigator · Awarded by National Institutes of Health · 2011 - 2017

EQAPOL - Option 48 - 2016 to 2017 - LUMINEX

ResearchInvestigator · Awarded by National Institutes of Health · 2010 - 2017

EQAPOL - 2016 to 2017 - Option 6 - BASE

ResearchInvestigator · Awarded by National Institutes of Health · 2010 - 2017

EQAPOL Option 5

ResearchInvestigator · Awarded by National Institutes of Health · 2010 - 2017

Animal Models of Infectious Diseases Part A

ResearchCo Investigator · Awarded by National Institutes of Health · 2010 - 2017

LC: HIV Vaccine Trials Network: Phase 1 PF

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2014 - 2015

HIV Vaccine Trials Network: LC P5 PF

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2014 - 2015

IQA Option 4

ResearchSafety Coordinator · Awarded by National Institutes of Health · 2007 - 2014

Production of HIV-1 Envs #2

ResearchInvestigator · Awarded by Foundation for the National Institutes of Health · 2012 - 2013

Mechanisms of Allogeneic Stem Cell Education in SCID

ResearchInvestigator · Awarded by National Institutes of Health · 1999 - 2012

Role Of Surfactant In Innate and Adaptive Immunity

ResearchConsultant · Awarded by National Institutes of Health · 2001 - 2011

Dose Study of Thymus Transplantation, IND 9836

ResearchConsultant · Awarded by Food and Drug Administration · 2005 - 2008

Thymic Transplantation in Complete DiGeorge Syndrome

ResearchInvestigator · Awarded by National Institutes of Health · 1999 - 2004

Memory T Cell Induction In Neonates By Viral Vaccines

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1996 - 2002

External Relationships


  • QualCon, Inc., a consulting company

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.